| 摘要 |
The invention relates to the pharmaceutical industry in general and to the industry involved in the manufacture of pharmaceutical products for loosing weight and treating diabetes. The invention is advantageous over prior art compositions in that it reduces risks of suffering hypoglycaemia, reduces progressive lose of glycaemic control, thereby enabling a reduction in doses and, consequently, the individual collateral effects; enabling an adequate control of posprandial glucose, and improving the lipid profile. In addition, the inventive composition comprises an anti-hypoglycaemic agent, and an (-glucosidase inhibitor. More particularly the composition comprises acarbose and pioglitazone.
|
